Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: A pilot study

Lupus

Volumn 9, Issue 9, 2000, Pages 688-695

  Ames, P R J ^a   Tommasino, C ^a   Alves, J ^a   Morrow, J D ^a   Iannaccone, L ^a   Fossati, G ^a   Caruso, S ^a   Caccavo, F ^a   Brancaccio, V ^a  

^a 75 Canterbury House ^*  (United Kingdom)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Microalbuminuria; Oxidation

Indexed keywords

ANTIOXIDANT; CARDIOLIPIN ANTIBODY; ENDOTHELIN 1; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN G; ISOPROSTANE; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PROBUCOL; PROTHROMBIN; THROMBOXANE B2; VON WILLEBRAND FACTOR;

ADULT; ANTIBODY TITER; ANTIOXIDANT ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; LIPID PEROXIDATION; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ALBUMINURIA; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ANTIOXIDANTS; ANTIPHOSPHOLIPID SYNDROME; ARACHIDONIC ACIDS; CREATININE; ENDOTHELIN-1; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; NITRIC OXIDE; PILOT PROJECTS; PROBUCOL; PROTHROMBIN; THROMBOSIS; THROMBOXANE B2; VON WILLEBRAND FACTOR; WARFARIN;

EID: 0034536685     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300677692516     Document Type: Article

References (47)

1. Mechanisms of autoantibody-mediated thrombosis
2. Antiphospholipid antibodies, haemostatic variables and thrombosis. A survey on 144 patients
3. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus
4. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency
5. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant
6. Elevated lipoprotein (a) and its association with impaired fibrinolysis in antiphospholipid syndrome
7. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies
8. 'Oxidative stress' in primary antiphospholipid syndrome
9. The isoprostanes. Current knowledge and directions for future research
10. The L-arginine-nitric oxide pathway
11. Interactions of oxidant stress and vascular reactivity
12. Free radical generated F2isoprostanes stimulates cell proliferation and endothelin-1 expression on endothelial cells
13. Endothelins
14. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1
15. Probucol inhibits oxidative modification of low density lipoprotein
16. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
17. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an intemational workshop
18. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans
19. Criteria for the diagnosis of lupus anticoagulants: An update
20. A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin
21. Urinary NO3-excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-name in rats
22. Identification of noncyclo-oxygenase derived prostanoid (F2-isoprostanes) metabolites in human urine and plasma
23. Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulphate micelle solutions
24. Protective effect of probucol on alloxan diabetes in rats
25. Ongoing prothrombotic state in patients with antiphospholipid antibodies: A role for increased lipid peroxidation
26. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E
27. Albuminuria reflects widespread vascular damage. The Steno hypothesis
28. Microalbuminuria as predictor of cardiovascular disease in non-diabetic subjects
29. Microalbuminuria in primary hypertension: Is it a marker of glomerular damage?
30. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients
31. Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane
32. Mesangial cell behavior in a three-dimensional extracellular matrix
33. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes
34. Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase
35. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors
36. Activation and potential interactions between the arachidonic acid and L-arginine: Nitric oxide pathways in glomerulonephritis
37. Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis
38. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol
39. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism
40. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives
41. Nitric oxide: Mediator, murderer and medicine
42. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
43. Oxidation of low-density lipoproteins: Questions of initiation, propagation, and the effect of antioxidants
44. Fibrin as a factor in atherogenesis
45. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and allcause mortality, especially among hypertensive subjects: Five year follow-up of the Hoom Study
46. The antiphospholipid syndrome: Ten years on
47. Induction of early atherosclerosis in LDL-receptor deficient mice immunised with beta2-glycoprotein I